Recombinant Mouse TNFSF9 (4-1BBL) (carrier-free) 100 µg
Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
Points clés
TNFSF9, also termed 4-1BBL and CD137L, is a type II transmembrane glycoprotein that belongs to the TNF ligand superfamily. This protein is mainly expressed on antigen presenting cells (APC), particularly B lymphocytes. The interaction of TNFSF9 and its receptor, CD137, which is mainly expressed on T cells, leads to activation of cytotoxic T cells. In addition, TNFSF9-CD137 interaction can reactivate anergic T lymphocytes as well as induce T cell proliferation. This molecule plays a role in optimal CD8 T cell response. Interestingly, it appears that TNFSF9 is able to act as a costimulatory molecule without the engagement of other costimulatory molecules such as CD28. TNFSF9 signaling on T cells has also been shown to limit T cell activation. CD137L is upregulated in peripheral CD14+ monocytes of chronic hepatitis B patients and is associated with liver cirrhosis. Human TNFSF9 shares 36% of its amino acid sequence with its murine counterpart. Mice deficient in TNFSF9 are predisposed to develop B-cell lymphomas.;
Garantie
Garantie 0 Mois
Description
TNFSF9, also termed 4-1BBL and CD137L, is a type II transmembrane glycoprotein that belongs to the TNF ligand superfamily. This protein is mainly expressed on antigen presenting cells (APC), particularly B lymphocytes. The interaction of TNFSF9 and its receptor, CD137, which is mainly expressed on T cells, leads to activation of cytotoxic T cells. In addition, TNFSF9-CD137 interaction can reactivate anergic T lymphocytes as well as induce T cell proliferation. This molecule plays a role in optimal CD8 T cell response. Interestingly, it appears that TNFSF9 is able to act as a costimulatory molecule without the engagement of other costimulatory molecules such as CD28. TNFSF9 signaling on T cells has also been shown to limit T cell activation. CD137L is upregulated in peripheral CD14+ monocytes of chronic hepatitis B patients and is associated with liver cirrhosis. Human TNFSF9 shares 36% of its amino acid sequence with its murine counterpart. Mice deficient in TNFSF9 are predisposed to develop B-cell lymphomas.;
Caractéristiques
- Fournisseur
- BioLegend Europe BV
- Marque
- BIOLEGEND
- Référence fabricant
- 754406
- Référence distributeur
- 754406
- Vendu par
- 100 μg
- Quantité
- N/A
- Lieu de fabrication
- USA
- Lieu de stockage
- Pays-Bas ou USA
- Soumis à carboglace
- non
- Classement dans le catalogue fournisseur
- Recombinant Protein
- Certification
- RUO
- Type d’application
- bioassay
- Type de produit
- Recombinant Protein
- Température de conservation (°C)
- -20 ou -70 °C
- Température de transport
- Blue Ice
- Organisme cible
- Mouse
- Source biologique
- CHO cells
- Seuil de coupure des masses moléculaires MWCO
- The 227 amino acid recombinant protein has a predicted molecular mass of approximately 25kD. The protein migrates at approximately 40 kD in DTT-reducing conditions and at approximately 70 kD in non-reducing conditions by SDS-PAGE. Da
- Concentration
- 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration, please enter the lot number in our online tools.
- Pureté
- >95%, as determined by Coomassie stained SDS-PAGE. %
- Matière dangereuse
- non
- Code douanier
- 38220000
- Classement NCBI
- 21950
- Nomenclature Nacres
- NA.77
- Nomenclature CEA
- SGP01
- Nomenclature IRSN
- 273
- Nomenclature INSERM
- NA.NA77
- Nomenclature CNRS
- NA77
- Nomenclature CHU
- 18.551
- Nomenclature DGOS
- LD11AOOO
- Reprise en cas d’erreur client
- non